- The document is a high-level guide that outlines the issues to consider in executing life sciences collaborations in the COVID-19 era.
- This includes areas such as governance, development and regulatory activities, manufacture and supply, commercialization, diligence, licenses and exclusivity, financial provisions, IP, representations, warranties and indemnifications, dispute resolution and risk management, and antitrust.
- Experts from 36 jurisdictions across Asia Pacific; Europe, Middle East & Africa; Latin America; and North America, provide insights to commonly asked questions around market access, clinical trials, IP risks and telemedicine.
- The checklist identifies the key strategic issues companies need to consider towards reopening, which are applicable to multiple jurisdictions.
- The tool features a healthcare & life sciences focused chapter which includes issues and recommendations related to digital health, clinical trials, market access and promotion, supply chain and contractual liabilities.
Baker McKenzie Hub
About US
We are a transactional powerhouse providing commercially-focused, end to end legal advice to maximise deal certainty and secure the intended value of transactions. Our 2,500 transactional lawyers combine money market sophistication with local market excellence. We lead on major transactions with expertise spanning banking and finance, capital markets, corporate finance, finance and restructuring, funds, M&A, private equity and projects. The combination of deep sector expertise, and our ability to work seamlessly across each of the countries where we operate, means we add unique value in shaping, negotiating and closing the deal.
Thought Leadership
Life Sciences Collaborations: Key Considerations in the COVID-19 Era
COVID-19: A Global Review of Healthcare and Life Sciences Industry Issues Guide
Reopening for Business: Essential Checklists for UK In-House Counsel